Welichem Reports Positive Phase IIa Clinical Results



    BURNABY, BC, Oct. 30 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI) is pleased to announce the positive results from its Phase IIa
clinical trial of its drug candidate, WBI-1001, a new, non-steroid, topical
cream treatment for atopic dermatitis (AD). In the trial, two concentrations
(0.5% and 1.0%) of WBI-1001 were tested against the placebo. Both WBI-1001
cream concentrations were superior to placebo in deceasing AD and showed an
excellent safety profile. Welichem plans to conduct further clinical trials
for WBI-1001 in 2009. "We are very pleased to be able to present such positive
results from the Company's clinical trial on atopic dermatitis," says Dr.
Genhui Chen, Chief Executive Officer of Welichem." AD is a major unmet medical
indication, and these positive results are of significance for our overall
strategy of developing WBI-1001 for the treatment of this disease and
additional conditions."
    This clinical phase IIa trial for WBI-1001 was a randomized,
double-blind, placebo-controlled study conducted in Montreal with the
objectives of evaluating the safety and efficacy of the cream on topically
treated patients. A total of 36 patients with mild-to-moderate AD were treated
with 0.5% or 1% of WBI-1001 cream or placebo twice daily for 28 days. No
serious side effects were reported in any of the groups and no patient dropped
out due to adverse side effects of the treatment. All primary efficacy indices
measured efficacy positively and WBI-1001 was significantly more efficacious
than placebo at one or both treatment doses for all indices at day 28, the end
of the treatment.
    There is currently no cure for AD, and most common treatments are
anti-inflammatory drugs (e.g. corticosteroids) or immunosuppressants ( e.g.
tarcolimus). AD represents a significant global market that is expected to
exceed $1 billion USD by 2010.

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements. The Company thus seeks safe harbour.

    %SEDAR: 00021386E




For further information:

For further information: Dr. Genhui Chen, CEO, Telephone: (604)
432-1703; Fax: (604) 432-1704, e-mail: gchen@welichem.com; please visit our
website www.welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890